Tüdőrák: vizsgálatok itt: Dél-Korea
170 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Busan, Cheongju-si, Seoul
- Életkor
- 18 év and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Cheongju-si, Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1. fázisTaking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Cheongju-si, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - No phaseNot yet taking people in Dél-KoreaRepotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 10
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07599007 - 1. fázisTaking peopleA Study of PHN-012 in Patients With Advanced Solid Tumors
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- Pheon Therapeutics
See details and how to joinNCT07127874 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Jinju, Seoul
- Életkor
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - 1. fázisTaking peopleA Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- Where
- Cheongju Chungbuk, Seongnam-si, Gyeonggi-do, Seoul
- Életkor
- 18 év to 90 év
- People
- 380 worldwide
- Run by
- Amgen
See details and how to joinNCT07037758 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- Gyeonggi-do, Seoul
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - 1. fázisTaking peopleA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391670 · EU 2025-521639-34-00 - 1. fázisTaking peoplePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 1/2. fázisTaking peopleA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 102
- Run by
- GI Innovation, Inc.
See details and how to joinNCT07172802 - 1/2. fázisTaking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- BundangGu SeongnamSi, Cheongju-si, GangnamGu, SeodaemunGu, Seongnam-si, Seoul, SongpaGu
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - 2. fázisTaking peopleLazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 47
- Run by
- Sehhoon Park
See details and how to joinNCT06106802 - 2. fázisTaking peopleClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 50
- Run by
- Sehhoon Park
See details and how to joinNCT06830694 - 2. fázisNot yet taking people in Dél-KoreaLurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
- Where
- Seoul
- Életkor
- 20 év and over
- People
- 69
- Run by
- Yonsei University
See details and how to joinNCT07640932 - 1/2. fázisFut, nem toborozA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Where
- Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 796 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05150691 - 1/2. fázisTaking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - No phaseNot yet taking people in Dél-KoreaEffect of Mechanical Power-based Lung-protective Ventilation During One-lung Ventilation
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 164
- Run by
- Samsung Medical Center
See details and how to joinNCT07772804 - 3. fázisFut, nem toborozPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Goyang-si, Namdong-gu, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00 - 1/2. fázisTaking peopleStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- Where
- Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 244 worldwide
- Run by
- Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04683250 - 2. fázisTaking peopleA Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 1173
- Run by
- Samsung Medical Center
See details and how to joinNCT07774520 - 1/2. fázisTaking peopleA Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- Where
- Cheongju-si, Seongnam-si, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 201 worldwide
- Run by
- Yuhan Corporation
See details and how to joinNCT06616766